Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AVXL – Anavex Life Sciences Corp.

Anavex Life Sciences Corp.
AVXL
$11.20
Name : Anavex Life Sciences Corp.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $956,667,072.00
EPSttm : -0.56
finviz dynamic chart for AVXL
Anavex Life Sciences Corp.
$11.20
0.88%
$0.1

Float Short %

30.46

Margin Of Safety %

Put/Call OI Ratio

0.4

EPS Next Q Diff

-0.01

EPS Last/This Y

-0.04

EPS This/Next Y

2.91

Price

11.2

Target Price

34.33

Analyst Recom

1

Performance Q

20.3

Relative Volume

0.84

Beta

0.8

Ticker: AVXL




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04AVXL10.790.390.3269283
2025-07-07AVXL9.990.390.5269491
2025-07-08AVXL10.190.390.1470179
2025-07-09AVXL10.760.390.7470602
2025-07-10AVXL11.170.390.6170721
2025-07-11AVXL11.110.400.2771215
2025-07-14AVXL11.490.390.3671693
2025-07-15AVXL10.860.400.5075645
2025-07-16AVXL11.260.410.4776406
2025-07-17AVXL11.040.420.0776856
2025-07-18AVXL10.980.440.1574702
2025-07-21AVXL11.150.400.2259358
2025-07-22AVXL11.180.400.7960096
2025-07-23AVXL13.40.400.1460628
2025-07-24AVXL12.760.390.6464552
2025-07-25AVXL12.120.400.2365361
2025-07-28AVXL11.520.400.0865877
2025-07-29AVXL11.380.400.1266605
2025-07-30AVXL11.150.401.0166882
2025-07-31AVXL11.290.400.1767312
2025-08-01AVXL11.280.402.4867873
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04AVXL10.79-3.6- -0.56
2025-07-07AVXL9.98-3.6- -0.56
2025-07-08AVXL10.19-3.6- -0.56
2025-07-09AVXL10.76-3.6- -0.56
2025-07-10AVXL11.18-3.6- -0.56
2025-07-11AVXL11.11-3.6- -0.56
2025-07-14AVXL11.48-3.6- -0.56
2025-07-15AVXL10.87-3.6- -0.56
2025-07-16AVXL11.26-3.6- -0.56
2025-07-17AVXL11.06-3.6- -0.56
2025-07-18AVXL11.00-3.6- -0.56
2025-07-21AVXL11.14-3.6- -0.56
2025-07-22AVXL11.18-3.6- -0.56
2025-07-23AVXL13.41-3.6- -0.56
2025-07-24AVXL12.74-3.6- -0.56
2025-07-25AVXL12.13-3.6- -0.56
2025-07-28AVXL11.49-3.6- -0.56
2025-07-29AVXL11.36-3.6- -0.56
2025-07-30AVXL11.17-3.6- -0.56
2025-07-31AVXL11.30-3.6- -0.56
2025-08-01AVXL11.20-3.6- -0.56
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04AVXL0.005.9330.55
2025-07-07AVXL0.005.9030.55
2025-07-08AVXL0.005.9030.55
2025-07-09AVXL0.005.9030.55
2025-07-10AVXL0.005.9030.55
2025-07-11AVXL0.005.9030.44
2025-07-14AVXL0.006.1330.44
2025-07-15AVXL0.006.1330.44
2025-07-16AVXL0.006.1330.44
2025-07-17AVXL0.006.1330.44
2025-07-18AVXL0.006.1330.43
2025-07-21AVXL0.005.8030.43
2025-07-22AVXL0.005.8030.43
2025-07-23AVXL0.005.8030.43
2025-07-24AVXL0.005.8030.43
2025-07-25AVXL0.005.8030.46
2025-07-28AVXL0.005.4230.46
2025-07-29AVXL0.005.4230.46
2025-07-30AVXL0.005.4230.46
2025-07-31AVXL0.005.4230.46
2025-08-01AVXL0.005.4230.46
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.13

Avg. EPS Est. Current Quarter

-0.14

Avg. EPS Est. Next Quarter

-0.14

Insider Transactions

Institutional Transactions

5.42

Beta

0.8

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

9

Growth Score

20

Sentiment Score

18

Actual DrawDown %

64.4

Max Drawdown 5-Year %

-88.3

Target Price

34.33

P/E

Forward P/E

7.95

PEG

P/S

P/B

9.58

P/Free Cash Flow

EPS

-0.56

Average EPS Est. Cur. Y​

-0.56

EPS Next Y. (Est.)

2.35

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.84

Return on Equity vs Sector %

-71

Return on Equity vs Industry %

-52.3

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.09

EBIT Estimation

Anavex Life Sciences Corp.
Sector: Healthcare
Industry: Biotechnology
Employees: 42
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against the Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
stock quote shares AVXL – Anavex Life Sciences Corp. Stock Price stock today
news today AVXL – Anavex Life Sciences Corp. stock forecast ,stock prediction 2023 2024 2025
marketwatch AVXL – Anavex Life Sciences Corp. yahoo finance google finance
stock history AVXL – Anavex Life Sciences Corp. invest stock market
stock prices AVXL premarket after hours
ticker AVXL fair value insiders trading